
NIFTY is a simple, safe, and highly accurate non-invasive DNA-based prenatal test that provides the ability to screen for the most common trisomies, as well as the ability to test for sex chromosome aneuploidies, trisomies 9,16, 22, deletion/duplication syndromes, and sex determination.
During pregnancy, DNA from the baby crosses into the mother's blood. The NIFTY test involves taking a small sample of blood (about 10 mL) from the pregnant woman and then analyzing it to detect chromosomal abnormalities in the fetus. The test is completely non-invasive and has no risk of abortion or intrauterine infection.
NIFTY was the first NIPT test to move to clinical trial stage in 2010, and was introduced in Europe in 2013. As of 2018, more than 6,000,000 NIFTY tests have been conducted worldwide.